Chikashi Takeda Executive Officer and Chief Financial Officer Nacho Abia Executive Officer and Chief Operating Officer Pierre Boisier Chief Quality Officer PLAY LIST from the beginning Consolidated Financial Results for the 3rd Quarter and Full-year Forecasts for Fiscal 2023 Disclaimer Highlights 01. Consolidated Financial Results and Business Review for the 3Q of Fiscal 2023 (FY Ending March 31, 2023) 3Q of Fiscal 2023 (1) Consolidated Financial Results 3Q of Fiscal 2023 (2) Endoscopic Solutions Division (ESD) 3Q of Fiscal 2023 (3) Therapeutic Solutions Division (TSD) Statement of Financial Position Consolidated Cash Flows 02. Forecasts for Fiscal 2023 Fiscal 2023 Consolidated Forecasts Fiscal 2023 Forecasts by Business Segment FDA Warning Letters and Efforts to Strengthen QARA @ Appendix Changes in Reporting Structure 3Q of Fiscal 2023 Factors that Affected Consolidated Operating Profit 3Q of Fiscal 2023 Discontinued Operation (Scientific Solutions Business) 3Q of Fiscal 2023 Results by Segment Factors that Affected Consolidated Cash Flows Key Product Catalysts: Endoscopic Solutions Division (As of Feb. 10, 2023) Key Product Catalysts: Therapeutic Solutions Division (As of Feb. 10, 2023) Expenditures, etc. Foreign Exchange and Sensitivity Q&A Q&A 1 Q&A 2 Q&A 3 Q&A 4 Q&A 5 Q&A 6 Back Next